SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that an abstract
entitled 'Synergistic antiretroviral activity of pyrophosphate analogue
ANX-201 paired with nucleoside reverse transcriptase inhibitors in vitro'
was accepted for presentation at the International AIDS Society Conference
on HIV Pathogenesis, Treatment and Prevention. The presentation is
scheduled for July 23rd. The conference takes place July 22-25, 2007 in
Sydney, Australia.
About ANX-201
ANX-201 (thiophosphonoformate) is a pyrophosphate analog and member of
a new class of reverse transcriptase inhibitor (RTI) that is designed as a
component of highly active antiretroviral therapy (HAART) for HIV. ANX-201
has been shown in vitro to re-sensitize nucleoside reverse transcriptase
inhibitor (NRTI)-resistant virus. The resistance profile of ANX-201 is
unique among RTIs reflecting the distinct mechanism of action of this novel
drug. ADVENTRX plans to initiate a Phase 1/2 clinical trial of ANX-201 as a
component of multi-drug therapy for the treatment of HIV during 2007.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the validity of research
results; the risk that preclinical results are not indicative of the
success of subsequent clinical trials and that products will not perform as
preclinical data suggests or as otherwise anticipated; unexpected adverse
side effects or inadequate therapeutic efficacy of ANX-201 and other
uncertainties inherent in the drug development process; the timing and
success of clinical trials; difficulties or delays in developing, testing,
manufacturing, and obtaining regulatory approval for ANX-201, including
receiving necessary regulatory approvals for clinical trials of ANX-201;
the risk that ADVENTRX will be unable to raise sufficient capital to fund
the projects necessary to meet its anticipated or stated goals and
milestones, including funding the continued development of ANX-201; and
other risks and uncertainties more fully described in ADVENTRX's press
releases and public filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov. ADVENTRX does not intend to update any forward-
looking statement, including as set forth in this press release, to reflect
events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/gh/cnoc/comp/920134.html/
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866; or Media, Amy Martini of
WeissComm Partners, +1-212-301-7223
|
